MUMBAI, India, Sept. 14, 2022 /PRNewswire/ — Singapore–headquartered Everstone Capital, personal fairness arm of the Everstone Group, (Everstone) proclaims the acquisition of a controlling stake in Softgel Healthcare (SHPL), a specialised area of interest dosage type centered manufacturing participant catering to the worldwide nutraceutical, pharmaceutical and OTC segments. This partnership goals to rework SHPL right into a scaled, diversified, and globally acknowledged contract analysis, growth, and manufacturing group in India with help of the strategic sources of Everstone.
Headquartered in Chennai, SHPL is a part of the Madras Pharma Group, a number one pharmaceutical contract manufacturing group in southern India, with 8 manufacturing amenities overlaying all dosage varieties. SHPL specializes in analysis, growth and manufacturing of sentimental gelatin capsules and probiotics. Its prospects span throughout the Americas, Africa, Asia and India with over 80% of its gross sales being in exports. It has a state-of-the-art manufacturing facility in Chennai, conforming to globally acknowledged certifications and registrations resembling USFDA, TGA, EU-GMP, Health Canada, amongst others.
Veda Corporate Advisors was the unique monetary advisor to SHPL and its shareholders.
Sharing his views on the funding, Sameer Sain, Co-founder & CEO, Everstone Group, mentioned, “We are delighted to partner with SHPL, Mr. Sulaiman and the management team lead by Dr Vijay Alagappan. The company, with its strong R&D capabilities and ability to manufacture products in advanced dosage forms, is well positioned to be a global leader in the CDMO segment. We believe that Everstone’s value creation playbook will help SHPL realize its global goals and propel the company into its next phase of growth.”
Puncham Mukim and Dr Arjun Oberoi, Managing Directors, Everstone Capital will be part of the board of SHFL.
Mr A. M. Sulaiman, Founder-Chairman of the Madras Group, mentioned, “We are delighted to have Everstone as a partner in SHPL as we move ahead into an exciting growth phase in this business. The investment from Everstone will accelerate organization learning to provide best-in-class products and services to our customers and become a manufacturer of choice.“
About SHPL
SHPL is a specialised area of interest dosage type centered CDMO participant servicing the worldwide nutraceutical, pharmaceutical and OTC segments. The firm has well-entrenched buyer relationships in over 40 international locations globally.
For extra info, go to https://softgelhealthcare.com and
About Everstone Capital
Singapore headquartered Everstone Capital, the personal fairness arm of the Everstone Group (www.everstonegroup.com), is a world agency dedicated to driving financial development and creating sustainable worth. With seven workplaces globally (Singapore, Mumbai, Delhi, Bengaluru, New York, Dubai and Mauritius), Everstone Capital focuses on the mid-market with management mindset and development bias; comprising better of breed investing, operations and strategic sources with important expertise and abilities.
For extra info, go to www.everstonecapital.com and
For extra particulars, contact:
Ayoshmita Biswas
[email protected]
Logo: https://mma.prnewswire.com/media/1897769/Everstone_Capital_Logo.jpg
